RxDoctor Payments Data

Susan Wegrzyn

Nurse Practitioner · Williamsville, NYNPI 1518086206

Payments from drug & device makers

$2,323in general payments, 2019–2025

Across 152 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Collegium Pharmaceutical, Inc.$920
  • Abbott$390
  • AbbVie$236
  • Scilex Pharmaceuticals Inc.$156
  • Nevro Corp.$147
  • Pfizer$115
  • plus $360 from 10 others

What the payments were for

  • Food & beverage$2,323100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,323 in reported general payments places this provider in the 90th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$81,164
Medicare patients
143
Services billed
974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,645$44,678
OxycontinOxycodone Hcl78$41,140
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen381$14,908
Xtampza ErOxycodone Myristate23$14,051
Pregabalin432$11,930
Tramadol Hcl ErTramadol Hcl85$8,728
MovantikNaloxegol Oxalate21$8,440
Morphine Sulfate ErMorphine Sulfate134$7,578
Gabapentin517$6,067
Buprenorphine14$4,268
Oxymorphone Hcl ErOxymorphone Hcl11$4,237
Tramadol Hcl457$3,784
Oxycodone Hcl242$3,737
Baclofen185$2,088
Tizanidine Hcl32$1,776

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$920$14,05123 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$16$4,55134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →